China-based small molecule drug developer Nanjing Zenshine Pharmaceuticals Co., Ltd reportedly raised over RMB 100 million in a Series B financing round. The round was led by Hankang Capital and included participation from Cybernaut, Yangzijiang Funds, Ennovation Ventures, and Matrix Partners China. The proceeds will be used to enhance the clinical and industrialization team, support a Phase III clinical study, and file a New Drug Application (NDA) for its next-generation anti-influenza drug ZX-7101A. Additionally, funds will be allocated for the pre-clinical development of anti-tumor drugs ZX-101A and ZX-4081.
Company Overview and Pipeline
Zenshine Pharma is actively developing six drugs in the anti-infection and oncology fields, with three currently at the clinical stage. The company is on track to submit an NDA for ZX-7101A this year, further expanding its presence in the pharmaceutical market.
Significance of the Funding
This Series B financing round is a significant milestone for Zenshine Pharmaceuticals, providing the necessary resources to accelerate its drug development pipeline. The investment will enable the company to advance its innovative therapies, potentially offering new treatment options for patients with influenza and various types of cancer.-Fineline Info & Tech
